Effect of Vancomycin After Catheter Replacement

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Randomized controlled trial of the effect of a single-dose intravenous Vancomycin after catheter replacement for suspected central line-associated bloodstream infection on resolution of infection in critically ill patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Zurich
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

Suspected central line-associated bloodstram infection defined as:

• Catheterization with a non-tunneled CVC and

• Clinical signs of local catheter infection or any increase in humoral inflammatory markers (PCT, CRP, WBC) or elevated body temperature ≥ 38.3°C not otherwise explained.

Baseline CRP at screening ≥ 100 mg/L

Exclusion Criteria:

• known positive blood cultures at the time of randomization

• High risk situation warranting immediate empiric antibiotic therapy:

• endovascular implant (prosthetic valve, pacemaker, vascular graft)

• high-risk for endocarditis warranting endocarditis-prophylaxis

• Septic shock

• Catheter replacement not feasible or no further indication for central venous catheterization

• Known hypersensitivity to vancomycin or any component of the formulation.

• Administration of Vancomycin, Teicoplanin, Daptomycin or Linezolid <48 hours before enrolment.

• Enrolment in another clinical study

• Pregnancy